15 Nov 2021
Protagonist Therapeutics Announces Positive Phase 2a Data Supporting the Potential Use of Rusfertide as a First-in-Class Therapy in Hereditary Hemochromatosis
Author: admintech | Filed under: Press ReleaseNEWARK, Calif., Nov. 15, 2021 /PRNewswire/ — Protagonist Therapeutics (Nasdaq: PTGX) (“Protagonist” or “the Company”) today announced results from a Phase 2a study in which rusfertide, an investigational new drug, is being evaluated for the treatment of hereditary hemochromatosis (HH)….